Showing 2301-2310 of 5771 results for "".
- Ribomic Announces Positive Topline Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-positive-topline-results-from-the-phase-1-2a-clinical-trial-of-rbm-007-sushi-study-in-subjects-with-wet-amd/2476656/Ribomic announced positive topline results from its SUSHI study, a phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet age-related macular degeneration (AMD). The SUSHI study achiev
- Amarantus Announces Issuance of US Patent Covering MANF Treatment of Wolfram’s Syndrome, Retinitis Pigmentosa, and Glaucomahttps://modernod.com/news/amarantus-announces-issuance-of-us-patent-covering-manf-treatment-of-wolframs-syndrome-retinitis-pigmentosa-and-glaucoma/2476653/Amarantus Bioscience Holdings announced that subsidiary MANF Therapeutics was issued US Patent No. 10,195,251 entitled “Methods of Treatment for Retinal Diseases Using MANF and CDNF” that covers the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) or cerebral dopamine
- Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disordershttps://modernod.com/news/invitae-announces-id-your-ird-program-to-expand-access-to-genetic-testing-for-inherited-retinal-disorders/2476648/Invitae announced the launch of “ID YOUR IRD,” an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD). “Identifying the genetic cause of an inherit
- SightLife Announces 100,000 Corneal Transplants in India Since Program Inception in 2009https://modernod.com/news/sightlife-announces-100000-corneal-transplants-in-india-since-program-inception-in-2009/2476639/SightLife announced that, together with its partners in India, 100,000 individuals suffering from corneal blindness have had their sight restored through a corneal transplant in the last 10 years since operations began in India. SightLife is a nonprofit global health organization dedicated to eli
- Allegro Ophthalmics Announces Positive Topline Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-announces-positive-topline-results-of-phase-2-study-evaluating-risuteganib-in-patients-with-intermediate-dry-amd/2476627/Allegro Ophthalmics announced positive topline results of its phase 2 study of risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD). The clinical trial met its primary endpoint with 48 percent of patients in the risuteganib arm gaining ≥ 8 letters of
- PECAA Annual Meeting Draws Record Attendancehttps://modernod.com/news/pecaa-annual-meeting-draws-record-attendence/2476621/PECAA (Professional Eye Care Associates of America) hosted its sold-out annual meeting May 16-18 at the JW Marriott Austin. The member-only event drew a record 900+ individuals from the PECAA community for a mix of bu
- Ocular Therapeutix Announces Receipt of C-Code and Pass-Through Payment Status for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza/2476614/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement code for Dextenza (dexamethasone ophthalmic insert). The code, C9048, is scheduled to become effective July 1, 2019.
- Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meetinghttps://modernod.com/news/immunocore-to-present-new-tebentafusp-imcgp100-data-in-advanced-melanoma-at-upcoming-2019-asco-annual-meeting/2476605/Immunocore Limited, a T cell receptor (TCR) biotechnology company, will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 3, 2019. Teben
- Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign for Iluvienhttps://modernod.com/news/alimera-sciences-announces-launch-of-direct-to-patient-marketing-campaign-for-iluvien/2476603/Alimera Sciences announced the launch of a direct-to-patient (DTP) marketing campaign intended to raise awareness and educate patients diagnosed with diabetic macular edema (DME) and their caregivers about the therapeutic and dosing benefits of Iluvien. The campaign will be supported by the websi
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara